> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Pfizer Covid Pill Reduces Hospitalization/Death: Study
- URL: https://www.fdaweb.com/pfizer-covid-pill-reduces-hospitalization-death-study/
- Published: 2021-11-16T12:00:00.000Z
- Updated: 2026-09-14T17:22:26.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5150589

Pfizer says it will submit new data as part of its rolling Emergency Use Authorization request for its Covid-19 oral antiviral Paxlovid (ritonavir) that showed the drug significantly reduced hospitalization and death. The data come from an interim analysis of the Phase 2/3 EPIC-HR (Evaluation of Protease Inhibition for COVID-19 in High-Risk Patients) study of non-hospitalized adult patients with Covid-19, who are at high risk of progressing to severe illness. Pfizer says the “scheduled interim analysis showed an 89% reduction in risk of Covid-19-related hospitalization or death from any cause compared to placebo in patients treated within three days of symptom onset (primary endpoint); 0.8% of patients who received Paxlovid were hospitalized through Day 28 following randomization (3/389 hospitalized with no deaths), compared to 7% of patients who received placebo and were hospitalized or died (27/385 hospitalized with seven subsequent deaths).”